Featured Publications Archives

Plasticity of the human IgM repertoire in response to long‐term spaceflight

2021-02-11T20:09:45-08:00October 13th, 2020|2020 Publications, Featured Publications, Publications|

Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms

2021-02-11T23:46:14-08:00March 21st, 2019|2019 Publications, Featured Publications, Publications|

A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

2021-02-11T23:49:39-08:00August 25th, 2018|2018 Publications, Featured Publications, Publications|

Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL

2021-02-11T23:54:51-08:00August 22nd, 2018|2018 Publications, Featured Publications, Publications|

Targeted Deep Sequencing Reveals Clinically Relevant Subclonal IgHV Rearrangements in Chronic Lymphocytic Leukemia

2021-02-12T18:36:01-08:00October 31st, 2016|2016 Publications, Featured Publications, Publications|

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Evaluation of Next-Generation Sequencing Versus Next-Generation Flow Cytometry for Minimal Residual Disease Detection in Chinese Patients with Multiple Myeloma

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

Plasticity of the human IgM repertoire in response to long‐term spaceflight

Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms

A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL

Targeted Deep Sequencing Reveals Clinically Relevant Subclonal IgHV Rearrangements in Chronic Lymphocytic Leukemia

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Evaluation of Next-Generation Sequencing Versus Next-Generation Flow Cytometry for Minimal Residual Disease Detection in Chinese Patients with Multiple Myeloma

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

Plasticity of the human IgM repertoire in response to long‐term spaceflight

Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms

A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL

Targeted Deep Sequencing Reveals Clinically Relevant Subclonal IgHV Rearrangements in Chronic Lymphocytic Leukemia

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.